Friday, 16 October 2026European Markets

METABOLIC EXPLORER Stock Over 34% Down In The Last 21 Sessions

Loading stream...

metabolic explorer (metex.pa), a biological chemistry firm listed on france's cac 40 index, experienced an unexpected 34.45% share price drop over 21 sessions from eur1.19 to eur0.78, experiencing five straight loss sessions en route. despite an overall cac 40 index increase to eur7,240.88 this happened despite this dip.

stock performance overview

metabolic explorer's precipitous price decline puts it significantly below its 52-week peak of eur2.78. metabolic explorer closed last session trading at eur0.76, representing an incredible 72.64% drop from its 52-week high of eur2.78.

about metabolic explorer

metabolic explorer specializes in industrial fermentation processes as a greener alternative to petrochemical processes, offering its products globally from propanediol and butyric acid, glycolic acid, l-valine and more - used in products as diverse as cosmetics, textiles, polymers and animal nutrition as well as serving as foundation materials for biomaterial synthesis. established in 1999 and headquartered in saint-beauzire france since then; however, profitability issues persist at this company that was founded 17 years ago.

financial performance

metabolic explorer's earnings per share for the trailing twelve months was an alarming eur-1.13; furthermore, its return on equity--an indicator of how well a company generates profits using shareholders' equity--was at an alarming negative -39.56%, reflecting an alarming downward trend. these numbers demonstrate its financial hardships while seemingly reflecting in its stock prices as they drop further and further away.

more news about metabolic explorer (metex.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com